Latest Articles
New Radiotheranostic Targets Discovered for Enhanced Diagnosis and Treatment of Endometrial Cancer - BIOENGINEER.ORG
New Radiotheranostic Targets Discovered for Enhanced Diagnosis and Treatment of Endometrial Cancer BIOENGINEER.ORG
Published: Sept. 4, 2025, 9:37 p.m.
New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer - EurekAlert!
New radiotheranostic targets identified for diagnosis and treatment of endometrial cancer EurekAlert!
Published: Sept. 4, 2025, 9:25 p.m.
Closing Deadly Gaps in Endometrial Cancer Care Outcomes - Medscape
Closing Deadly Gaps in Endometrial Cancer Care Outcomes Medscape
Published: Sept. 4, 2025, 1:52 p.m.
Johor Hospital completes first robotic surgery for endometrial cancer - MSN
Johor Hospital completes first robotic surgery for endometrial cancer MSN
Published: Sept. 4, 2025, 1:14 p.m.
Age, Race Play a Role in Endometrial Cancer Outcomes - Cancer Nursing Today
Age, Race Play a Role in Endometrial Cancer Outcomes Cancer Nursing Today
Published: Sept. 3, 2025, 11:02 p.m.
XPR1: Emerging Prognostic Marker in Endometrial Cancer - BIOENGINEER.ORG
XPR1: Emerging Prognostic Marker in Endometrial Cancer BIOENGINEER.ORG
Published: Sept. 2, 2025, 9:51 a.m.
Lactate-Induced M2 Macrophages Boost Endometrial Cancer Progression - BIOENGINEER.ORG
Lactate-Induced M2 Macrophages Boost Endometrial Cancer Progression BIOENGINEER.ORG
Published: Aug. 29, 2025, 10:40 p.m.
Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery - Frontiers
Research progress of probiotics intervention on reconstruction of intestinal flora and improvement of quality of life in patients after endometrial cancer surgery Frontiers
Published: Aug. 29, 2025, 7:07 p.m.
Survival Varies by Age With HT in Endometrial Cancer - Medscape
Survival Varies by Age With HT in Endometrial Cancer Medscape
Published: Aug. 28, 2025, 3:05 p.m.
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. - AInvest
Genmab shares rise 1.21% premarket after FDA grants Breakthrough Therapy Designation to Rina-S for endometrial cancer treatment. AInvest
Published: Aug. 28, 2025, 8:24 a.m.
Link copied to clipboard!